ABCD is pleased to announce the launch of the ABCD nationwide IDegLira (Xultophy) audit and would like to invite you to take part.
The clinical trials of IDegLira seem to show in those uncontrolled on basal insulin (20-50units), IDegLira showed statistically improved HbA1c reductions in comparison to the up titration of insulin glargine U100 with fewer hypoglycamic episodes and less weight gain, and indeed with weight loss.
We hope through this nationwide audit to find out if these findings from the clinical trials translate into the same advantages when the agent is used in real clinical practice. The audit will be hosted on a tool very similar to that used in the liraglutide audit and the degludec audit so the many contributors taking part in those audits will find it particularly easy.
The online tool for the audit has a very easy to use sophisticated data analysis tool making it quick and easy to analyse your own local audit data. An ideal project for SpR, DSN or medical student if you do not have time yourself.
To register for the audit click HERE
To find out more click HERE
ALL CONTRIBUTORS TO THE AUDIT WILL BE LISTED ON PUBLICATIONS AND PRESENTATIONS ETC - EXACTLY AS OCCURRED IN OUR PREVIOUS AUDITS.
